Proteinuria
3
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
2
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Travere TherapeuticsSparsentan
Bristol Myers SquibbBelatacept
Clinical Trials (2)
Total enrollment: 35 patients across 2 trials
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
Start: Oct 2025Est. completion: May 202720 patients
Phase 4Recruiting
Belatacept Conversion in Proteinuric Kidney Transplant Recipients
Start: Oct 2015Est. completion: Oct 202015 patients
Phase 2Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 35 patients
2 companies competing in this space